Synopsis: In this episode of Biotech 2050, Alex Martin, CEO of Abcuro, sits down with host Rahul Chaturvedi to share his inspiring journey from aspiring actor to biotech trailblazer. Alex reveals how his unique background shaped his leadership approach as he drives Abcuro’s groundbreaking work on Inclusion Body Myositis (IBM), a rare muscle disease with no current treatments. He offers valuable insights for biotech CEOs on navigating the complexities of fundraising, building mission-driven teams, and fostering productive relationships with boards. Tune in to discover how Alex is leading Abcuro to the forefront of biotech innovation and making a profound impact on patient lives. Biography: Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA Pharma (EPIX). He was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT), and Chief Finance Officer of BioXell (BXLN) which was acquired by Cosmo Pharmaceuticals (COPN). He began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. Alex is an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. He holds a BA from Cornell University and an MBA from Harvard.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related